Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

News
Video

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Related Content
Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.

CB-012 Earns FDA Fast Track Status in R/R Acute Myeloid Leukemia

Russ Conroy
September 4th 2024
Article

Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Muhammad Hamza Gul, MBBS, MD;Aisha Rehman Siddiqui, MBBS, MD;Farwa Zehra, MBBS;Malaika Rehmani, MBBS;Faraz Waheed, MBBS;Natasha Masood, MBBS;Maleeha Saqib, MBBS;Mahnoor Keen, MBBS, MD;Sharan Siddharth Keshetty, MD;Maham Maqsood, MBBS;Siddharth Arjun Atwal, MD;Muhammad Hamza Sikandari, MBBS;Abdul Baseer Wardak, MBBS
August 19th 2024
Article

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

The FDA has advised developers to attain overall survival benefit in a randomized head-to-head trial to support a BLA filing for Iomab-B.

SIERRA Results Do Not Support BLA Filing for 131I-Apamistamab in R/R AML

Roman Fabbricatore
August 6th 2024
Article

The FDA has advised developers to attain overall survival benefit in a randomized head-to-head trial to support a BLA filing for Iomab-B.

An overall survival and 3-year relapse-free survival advantage was seen with blinatumomab vs chemotherapy alone in a phase 3 trial of B-cell precursor subtype ALL.

Blinatumomab/Chemo Combo Shows Improved Survival In B-Cell Precursor ALL

Roman Fabbricatore
August 6th 2024
Article

An overall survival and 3-year relapse-free survival advantage was seen with blinatumomab vs chemotherapy alone in a phase 3 trial of B-cell precursor subtype ALL.